(Q45250754)

English

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

scientific article published on 30 May 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

M Siebels

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

K Rohrmann

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

R Oberneder

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M Stahler

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

N Haseke

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

J Beck

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

R Hofmann

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M Kindler

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

P Kloepfer

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

C Stief

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

publication date

30 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

World Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

121-126

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Fra

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma: management of advanced disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The changing natural history of renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20512580

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00345-010-0570-2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45250754&oldid=2207173457"